Valued at USD 1,656.88 million in 2024, the market is expected to expand at a CAGR of 6.83% from 2025 to 2032, reaching approximately USD 2,806.85 million by the end of the period. This upward trajectory is driven by the growing prevalence of neurological and cardiovascular diseases—including acute ischemic stroke, pulmonary embolism, and deep vein thrombosis—which are increasing the demand for effective, timely interventions.
Moreover, the rising adoption of minimally invasive procedures, known for their safety, shorter recovery periods, and improved patient outcomes, is further fueling market growth. Continuous technological innovations, strategic product launches, and investments by leading device manufacturers are enhancing procedural efficiency and broadening therapeutic options. Collectively, these trends are setting the stage for sustained market expansion through 2032.
DelveInsight’s Thrombectomy Devices Market Insights report offers an in-depth analysis of current and forecast market trends, competitive dynamics, key drivers and challenges, as well as profiles of leading thrombectomy device manufacturers.
Request for a sample report: https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Thrombectomy Devices Market Report
-
The Thrombectomy Devices Market is expected to witness steady growth at a moderate CAGR from 2025 to 2032. According to DelveInsight’s analysis, North America is projected to lead the global market throughout the forecast period.
-
Prominent industry participants include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Mermaid Medical, Surmodics, Penumbra, Medtronic, Johnson & Johnson Services, Edwards Lifesciences, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., Zylox-Tonbridge Medical Technology Co., Ltd., and several others actively contributing to market innovation and expansion.
-
In February 2025, Stryker completed its acquisition of Inari Medical, Inc., a move that substantially strengthens its position in the thrombectomy devices sector. Inari’s cutting-edge technologies—such as the FlowTriever® System for pulmonary embolism and the ClotTriever® System for peripheral thrombectomy—complement Stryker’s existing Neurovascular portfolio, broadening its therapeutic reach.
-
Also in February 2025, Shanghai Tendfo Medical Device Co., Ltd. obtained NMPA approval in China for its Tendvia™ Pulmonary Artery Thrombectomy System, designed for transcatheter thrombus removal in patients with acute high- or intermediate-risk pulmonary embolism, offering a minimally invasive treatment approach for these critical cases.
-
Earlier, in September 2024, Argon Medical Devices introduced the CLEANER Vac™ Thrombectomy System, a single-use, large-bore aspiration device engineered to swiftly and effectively remove thrombus from the peripheral venous system, improving blood flow restoration.
-
In January 2023, phenox Inc. received FDA 510(k) clearance for its pRESET® Thrombectomy Device, designed to mechanically remove clots and restore blood circulation in patients experiencing acute ischemic stroke.
To read more about the latest highlights related to the Thrombectomy Devices market, get a snapshot of the key highlights entailed in the Global Thrombectomy Devices Market Report
Thrombectomy Devices Overview
Thrombectomy devices are advanced medical tools designed to extract blood clots (thrombi) from blood vessels, helping restore proper blood circulation and prevent tissue injury or necrosis. They are primarily utilized in emergency medical situations to manage conditions such as ischemic stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and acute limb ischemia (ALI).
Thrombectomy Devices Market Insights
North America is expected to dominate the global thrombectomy devices market in 2024, driven by several key factors. These include the high prevalence of neurovascular, peripheral, and coronary vascular diseases, a rapidly growing elderly population, and continuous innovation and product development by leading regional medical device manufacturers. Moreover, the region benefits from advanced healthcare infrastructure, supportive reimbursement policies, and increasing awareness of minimally invasive procedures, all of which support its market leadership.
Data from the Centers for Disease Control and Prevention (CDC, 2024) indicate that over 795,000 strokes occur in the United States each year, with roughly 185,000—about one in four—affecting individuals with a prior stroke history. The CDC also estimates that approximately 900,000 people in the U.S. experience venous thromboembolism (VTE) annually. These statistics highlight the significant burden of thromboembolic disorders and the critical need for thrombectomy devices, which mechanically remove clots and restore blood flow.
Coronary heart disease (CHD) further drives market growth. According to CDC data released in June 2024, around 20.5 million Americans were living with CHD in 2022, while approximately 6.5 million individuals aged 40 and older had been diagnosed with peripheral artery disease (PAD). The rising prevalence of these vascular conditions underscores the vital role of thrombectomy devices in improving patient outcomes and reinforces North America’s strong position in the global market.
To know more about why North America is leading the market growth in the Thrombectomy Devices market, get a snapshot of the Thrombectomy Devices Market Outlook
Thrombectomy Devices Market Dynamics
According to the British Heart Foundation (2024), around 56 million women and 45 million men worldwide were living as stroke survivors, highlighting the substantial global burden of cerebrovascular disease. The report also noted that nearly 250 million people were affected by coronary heart disease as of 2022, emphasizing the critical need for effective interventional treatments. Similarly, the World Stroke Organization (2023) estimated that one in four adults over 25 is likely to experience a stroke in their lifetime, with more than 110 million people globally having already suffered one. In such scenarios, thrombectomy devices play a vital role by physically removing clots from blocked arteries or veins to restore blood flow, a function especially crucial during emergency conditions like ischemic stroke or peripheral arterial thrombosis.
Furthermore, the National Institutes of Health (2022) reported that over 17,000 Australians develop venous thromboembolism (VTE) each year, reflecting the rising prevalence of clot-related disorders and the urgent need for effective interventions such as thrombectomy procedures.
More recent findings from the British Heart Foundation (2025) revealed that over 7.6 million individuals in the UK were living with heart and circulatory diseases in 2024, including 4 million men and 3.6 million women. These numbers are projected to increase by 1 million by 2030 and 2 million by 2040, underscoring the growing demand for advanced medical solutions like thrombectomy devices that can rapidly and efficiently remove clots, restore circulation, and improve outcomes for patients with serious cardiovascular conditions.
Thrombectomy Devices Market Drivers:
-
Growing prevalence of neurological and cardiovascular diseases
-
Increasing product development activities
Get a sneak peek at the Thrombectomy Devices market dynamics @ https://www.delveinsight.com/report-store/thrombectomy-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Thrombectomy Devices Market Report:
-
Coverage: Global
-
Study Period: 2022 to 2032
-
Key Thrombectomy Devices Companies: Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.
Which MedTech key players in the Thrombectomy Devices market are set to emerge as the trendsetter, explore @ Thrombectomy Devices Companies
Table of Contents
1. Thrombectomy Devices Market Report Introduction
2. Thrombectomy Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Thrombectomy Devices Market Key Factors Analysis
6. Thrombectomy Devices Market Porter’s Five Forces Analysis
7. Thrombectomy Devices Market Layout
8. Thrombectomy Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
